Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study Investigating the Effects of Acetyl-L-Carnitine and Vincristine-Induced Neuropathy in Pediatric Patients With ALL

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must meet the following inclusion criteria.~  * The subject must have a confirmed diagnosis of acute lymphoblastic leukemia within 1 week of starting therapy~ * Currently being treated on a standard ALL induction regimen~ * Subjects must be greater than or equal to 5 and less than 18 years old~ * Signed informed consent~Exclusion Criteria:~* Subjects will be excluded for the following:~  * Preexisting neurologic disease, including grade II, III, or IV neurological status by NCI Common Toxicity Criteria v3.0 on clinical exam~ * History of hypersensitivity to vincristine~ * History of hypersensitivity to Acetyl-L-carnitine~ * Previous use of Acetyl-L-carnitine~ * Concurrent anti-convulsant use~ * Concurrent Gabapentin use~ * Concurrent Glutamine use~ * Liver Function: Total bilirubin greater than 1.3 mg/dL and serum glutamic-pyruvic transaminase (SGPT) (ALT) greater than 5 x upper limit of normal for age and serum albumin less than 2 g/dL~ * Patients who are pregnant

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Acetyl-L-Carnitine only (Type: EXPERIMENTAL): The first 15 subjects participating in this study will receive Acetyl-L-Carnitine and pharmacokinetic testing will be done.
- Acetyl-L-Carnitine or Placebo (Type: EXPERIMENTAL): Subjects 16-30 will be randomized to receive drug or placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).